Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

One finding in particular caught Ding’s attention. Hypomethylation on fibroblast growth factor receptor 2 (FGFR2), a receptor tyrosine kinase (RTK) oncogene, increased transcript and protein abundance ...

The research delves into how mutations in FGFR2 and FGFR3 affect mandibular ... Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal ...

Fibroblast growth factor receptors (FGFRs ... However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field.

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients with FGFR2/3 mutations. With the growing emphasis on ...

Hutchmed (HCM) announced that it has completed enrollment of its a Phase II trial of fanregratinib for intrahepatic cholangiocarcinoma patients ...